AstraZeneca’s Landmark Collaboration Agreement For A Potential COVID-19 Vaccine


Gowling WLG advised AstraZeneca on a landmark collaboration agreement for the development and distribution of the University of Oxford’s potential COVID-19 vaccine. Bristows LLP advised the University of Oxford.

Under the agreement, AstraZeneca will be responsible for development and worldwide manufacturing and distribution of the vaccine.

The arrangement will enable the two organisations to globally develop, manufacture and distribute the University’s potential new recombinant adenovirus vaccine (known as ChAdOx1 nCoV-19). The vaccine, being developed by the Jenner Institute and Oxford Vaccine Group at the University of Oxford, aims to prevent COVID-19 infection from SARS-CoV-2.

The potential vaccine entered Phase I clinical in April. This phase focuses on studying safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in the South of England. The resulting data from this phase is expected shortly which, if positive, would lead to late-stage trials in a number of countries.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the areas of oncology, cardiovascular, renal & metabolism and respiratory & immunology. AstraZeneca operates in more than 100 countries and its medicines are used worldwide.

Head of life sciences Patrick Duxbury (Picture) and director Jenny Davies worked on the deal with AstraZeneca Assistant General Counsel, Corporate, Maryam Abdul-Kareem; finalising the terms of a deal first highlighted in the Prime Minister’s COVID-19 briefing earlier this month.

Involved fees earner: Jenny Davies – Gowling WLG; Patrick Duxbury – Gowling WLG;

Law Firms: Gowling WLG;

Clients: AstraZeneca;